

Original article

Prevalence of Stable Angina in Spain. Results of the OFRECE Study



Joaquín J. Alonso,^{a,*} Javier Muñoz,^b Juan José Gómez-Doblas,^c Gustavo Rodríguez-Roca,^d José María Lobos,^e Gaietà Permanyer-Miralda,^f Manuel Anguita,^g Francisco Javier Chorro,^h and Eulàlia Roigⁱ on behalf of the OFRECE study researchers

^aServicio de Cardiología, Hospital Universitario de Getafe, Getafe, Madrid, Spain

^bInstituto de Ciencias de la Salud, Universidad de A Coruña, INIBIC, A Coruña, Spain

^cServicio de Cardiología, Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain

^dCentro de Salud La Puebla de Montalbán, Toledo, Spain

^eCentro de Salud Villablanca, Madrid, Spain

^fServicio de Cardiología, Hospital Universitario Vall d'Hebron, Barcelona, Spain

^gServicio de Cardiología, Hospital Reina Sofía, Córdoba, Spain

^hServicio de Cardiología, Hospital Clínico Universitario de Valencia, Valencia, Spain

ⁱServicio de Cardiología, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

Article history:

Received 14 April 2014

Accepted 9 September 2014

Available online 17 February 2015

Keywords:

Stable angina

Ischemic heart disease

Chronic coronary artery disease

Prevalence

Epidemiology

ABSTRACT

Introduction and objectives: The objective of the OFRECE study was to estimate the prevalence of stable angina in Spain. This prevalence is currently unknown, due to a lack of recent studies and to changes in the epidemiology and treatment of ischemic heart disease.

Methods: This cross-sectional study involved a representative sample of the Spanish population aged 40 years or older, obtained via 2-stage random sampling: in the first stage, primary care physicians were randomly selected from each Spanish province, whereas in the second stage 20 people were selected from the population assigned to each physician. The prevalence was weighted by age, sex, and geographical area. Participants were classified as having angina if they met the "definite angina" criteria of the Rose questionnaire and as having confirmed angina if the angina was confirmed by a cardiologist or if they had a history of acute ischemic heart disease or revascularization.

Results: Of the 11 831 people invited to participate, 8378 (71%) were analyzed (mean age, 59.2 years). The weighted prevalence of definite angina (Rose) was 2.6% (95% confidence interval, 2.1%-3.1%) and was higher in women (2.9%) than in men (2.2%), whereas that of confirmed angina was 1.4% (95% confidence interval, 1.0%-1.8%), without differences between men (1.5%) and women (1.3%). The prevalence of definite angina (Rose) increased with age (0.7% in patients aged 40 to 49 years and 7.1% in those aged 70 years or older), history of cardiovascular disease, and cardiovascular risk factors, except smoking.

Conclusions: The prevalence of definite angina (Rose) in the Spanish population aged 40 years or older was 2.6%, whereas that of confirmed angina was 1.4%. Both prevalences increased with age, cardiovascular risk factors, and cardiovascular history.

© 2014 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved.

Prevalencia de angina estable en España. Resultados del estudio OFRECE

RESUMEN

Introducción y objetivos: El objetivo del estudio OFRECE fue estimar la prevalencia de angina estable en España. Esta es actualmente desconocida por falta de estudios recientes y cambios en la epidemiología y el tratamiento de la cardiopatía isquémica.

Métodos: Estudio transversal. Se obtuvo una muestra representativa de la población española de edad mayor o igual a 40 años mediante muestreo aleatorio en dos etapas: la primera fue una selección aleatoria de médicos de atención primaria de cada provincia y la segunda, una selección de 20 individuos de la población asignada a cada médico. La prevalencia se ponderó por edad, sexo y área geográfica. Se clasificó a los participantes como pacientes con angina si cumplían criterios de «angina segura» del cuestionario de Rose y como angina confirmada si además tenían antecedentes de cardiopatía isquémica aguda, revascularización o confirmación tras evaluación cardiológica.

Palabras clave:

Angina estable

Cardiopatía isquémica

Enfermedad coronaria crónica

Prevalencia

Epidemiología

* Corresponding author: Servicio de Cardiología, Hospital Universitario de Getafe, Carretera de Toledo Km 12,500, 28905 Getafe, Madrid, Spain.

E-mail address: joaquinjesus.alonso@salud.madrid.org (J.J. Alonso).

◇ A list of the contributors to the OFRECE (*Observación de Fibrilación y Enfermedad Coronaria en España* [Observation of Fibrillation and Coronary Disease in Spain]) study is included in [Appendix 1 of the supplementary material](#).

Resultados: Se analizó a 8.378 personas (media de edad, 59,2 años), el 71% de las 11.831 invitadas a participar. La prevalencia ponderada de angina segura (Rose) fue del 2,6% (intervalo de confianza del 95%, 2,1–3,1%), mayor en mujeres (2,9%) que en varones (2,2%), y la de angina confirmada, del 1,4% (intervalo de confianza del 95%, 1,0–1,8%) sin diferencias entre varones (1,5%) y mujeres (1,3%). La prevalencia se incrementó con la edad (angina segura, el 0,7% en el grupo de 40–49 años y el 7,1% en el de mayor o igual a 70 años), los antecedentes de enfermedad cardiovascular y los factores de riesgo cardiovascular, salvo el tabaquismo.

Conclusiones: La prevalencia de angina segura (Rose) en la población española de edad mayor o igual a 40 años es del 2,6% y la de angina confirmada, del 1,4%, y ambas se incrementan con la edad, los factores de riesgo cardiovascular y los antecedentes cardiovasculares.

© 2014 Sociedad Española de Cardiología. Publicado por Elsevier España, S.L.U. Todos los derechos reservados.

Abbreviations

ACS: acute coronary syndrome
PC: primary care

INTRODUCTION

In recent decades, significant advances have been made in the understanding of the pathophysiology and pharmacological and interventional treatment of coronary artery disease. At the same time, developed countries have launched preventive interventions against cardiovascular risk factors (CVRFs). Both aspects should have contributed to improve the epidemiological data and prognosis of ischemic heart disease.^{1–3} Although the prevalence of stable angina in Spain has been evaluated in various population studies, none has been recent. These studies estimated a 2% to 4% prevalence of stable angina, with marked regional variations.⁴ In the United States, an analysis of studies of acute coronary syndrome (ACS) led to an estimate of 16.5 million people with angina (prevalence of 5.3%) via analysis of ACS.⁵ Nonetheless, advances in preventive intervention and treatment should have decreased the incidence of ischemic heart disease and increased the number of asymptomatic patients after diagnosis.^{6,7} Therefore, the prevalence of stable angina has probably changed.

In Spain, the prevalence of stable angina has been examined in only 2 population studies (PANES⁸ and REGICOR⁹). The PANES study showed a high prevalence of stable angina (7.5%), attributable in part to the study methodology, whereas the REGICOR study reported a prevalence of only 3.5%. The latter study was performed in a specific area of Girona province and in individuals aged between 24 and 75 years. The main limitation of both studies is that they were performed more than 15 years ago and probably no longer reflect the current situation. Thus, a new evaluation of the prevalence of stable angina in Spain seems pertinent. The main objective of the OFRECE¹⁰ study was to estimate the prevalence of atrial fibrillation and stable angina in the Spanish population aged 40 years or older, stratified by age (decades) and sex. This article provides information on the current prevalence of stable angina.

METHODS

Design and Definitions

The present cross-sectional study of the Spanish population aged 40 years or older was conducted in primary care (PC).

The OFRECE study was approved by the Ethics Committee for Clinical Research of *Hospital Universitario de Basurto*. The main characteristics of its methodology have already been described.¹⁰ Briefly, to obtain a representative sample of the Spanish population, for each Spanish province one hospital and health care area (2 in Madrid and Barcelona) and one cardiologist were selected. The cardiologists acted as study coordinators. Ultimately, 46 provinces and 47 hospitals and cardiologists participated. Four provinces and the second center in Madrid were excluded or failed to participate due to various logistic problems. The next step was multistage random sampling. All PC physicians of the area assigned to each hospital were identified and 10 physicians from each area were selected by simple random sampling. In total, the participating hospitals contained 7959 PC physicians attending 340 883 persons older than 39 years. Of the 769 physicians invited to participate, 425 (55.2%) accepted (Figure 1). Of the population aged 40 years or older assigned to each participating PC physician, a sufficient number were selected by simple random sampling to obtain 20 individuals per physician. At this stage, 76% of those invited agreed to participate (n = 8400). All participants provided informed consent. The study was carried out from March 2010 through October 2012. Only 22 participants had to be withdrawn from the final analysis of the prevalence of angina (4 due to missing key information and 18 for failing to fully complete the form on angina, which included the Rose questionnaire). The final sample for the analysis of the prevalence of stable angina was 8378 people (Figure 1).

All participants were examined by their PC physician who, with the clinical history and other information provided by the patient, completed questionnaires/forms on CVRFs and medical history, atrial fibrillation, and angina (Rose questionnaire).^{8,11,12} The Rose questionnaire has 7 test-type questions (Appendix 2 of the supplementary material) with 4 to 7 possible answers. Based on the answers, the patients were classified as: a) without angina; b) having definite angina; c) having possible angina, and d) having atypical angina. Patients were only considered to have angina if they met all “definite angina” criteria. In addition, all participants underwent an electrocardiogram and measurements of their weight, height, and blood pressure (2 measurements, in accordance with World Health Organization guidelines). If the existence of an unknown heart disease was suspected during a clinic visit, an appointment was made for the patient with the coordinating cardiologist and the patient was informed of the need for a full diagnostic workup. The various clinical variables were defined according to the guidelines of the American College of Cardiology/American Heart Association for atrial fibrillation¹³ and are described in the first publication from this study.¹⁰ Participants were given a diagnosis of previous ischemic heart disease only if it was documented that they had already had myocardial infarction, unstable angina, or revascularization.

Two definitions of angina were used: a) definite angina: when participants were classified as having definite angina by the Rose




Figure 1. Flow diagram of participation in the OFRECE study relative to angina analysis. ^aMadrid participated with only 1 of the 2 previously selected centers. ^bBarcelona (2 hospitals participated). ^cReasons for losses: unreachable after attempted postal and/or telephone contact; participant refusal: lack of interest (personal or work reasons preventing attendance at the center to participate in the study); unknown: unspecified cause.

questionnaire, and *b*) confirmed angina: when participants with “definite angina” (Rose questionnaire) also had one of the following conditions:

- Diagnosis confirmed by a cardiologist after complete evaluation.
- Previous diagnosis of documented myocardial infarction, unstable confirmed angina, or coronary revascularization.

Statistical Analysis

The sampling process gave each individual in the population a different probability of being selected. Therefore, a weight was assigned to each participant in the final sample to reflect the number of people of the Spanish population from the same age group, sex, and geographical area represented by this participant.¹⁴ Weighting was performed in 2 phases. As the study used a 2-stage sampling design, the first phase was to calculate the weight of the design as the inverse of the selection probability for each

individual in each stage of the sampling process. For the first stage (physician selection), the selection probability for each province was calculated using the number of PC physicians in the province. For the second stage (participant selection), the denominator was the number of people aged ≥ 40 years assigned to each physician. In the second phase, reweighting was performed to adjust the sample distribution to that of the population according to age and sex, variables related to the outcome but not considered in the sampling process. This reweighting applied the procedure proposed by Deville and Särndal¹⁵ using the *calibrate* instruction of the Stata v10.1 statistical software package (all analyses were performed using this program). To adjust or calibrate the sample, the population used was the municipal census of 2011. In the case of definite and confirmed angina, the weighted prevalences were calculated by age and sex according to the population distribution and 95% confidence intervals (95% CIs). In the methodology used to calculate the confidence intervals of the prevalences, the variance of the proportion estimator was

Table 1

General Characteristics (Demographic Data, Cardiovascular Risk Factors, and History) of the Study Population and of the Patients With Definite Angina (Rose Questionnaire) and Confirmed Angina. Comparison Between Patients With Angina (Definite or Confirmed) and the Rest of the Population

	All	Definite angina (Rose)			Confirmed angina		
		Yes	No	P	Yes	No	P
Participants, No.	8378	210	8168		117	8261	
Sex, %							
Men	47.4	40.4	47.6	.156	53.0	45.7	.448
Women	52.6	59.6	52.4		47.0	54.3	
Age group, %							
40–49 y	31.2	8.4	31.8	< .001	6.4	31.6	< .001
50–59 y	24.5	16.3	24.7		18.5	24.6	
60–69 y	19.3	13.1	19.5		10.7	19.4	
70–79 y	14.9	40.7	14.2		46.9	14.5	
≥ 80 y	10.1	21.5	9.8		17.6	10.0	
Cardiovascular risk factors							
Obesity, %	33.7	49.7	33.3	< .001	47.1	33.5	.035
Overweight, %	42.0	36.1	42.2	.159	37.5	42.1	.491
BMI, mean	28.40	30.09	28.40	.011	29.80	28.40	< .001
Central obesity, %	55.6	75.0	55.1	< .001	76.9	55.3	< .001
Hypercholesterolemia, %	25.3	63.9	24.3	< .001	75.6	24.6	< .001
Diabetes mellitus, %	12.2	29.3	11.7	< .001	28.9	11.9	< .001
Current smoker, %	22.2	8.5	22.6	< .001	11.0	22.4	.012
Hypertension, %	45.3	71.4	44.6	< .001	83.5	44.8	< .001
SBP (mmHg), mean	130.90	131.74	130.90	.834	131.80	130.90	.564
DBP (mmHg), mean	77.80	76.24	77.90	.012	74.20	77.9	.101
History, %							
Stroke	3.8	9.5	3.6	< .001	14.0	3.6	< .001
Peripheral artery disease	2.4	8.9	2.2	< .001	11.3	2.2	< .001
Chronic pulmonary disease	6.3	14.8	6.0	< .001	17.7	6.1	< .001
Thyroid disease	6.9	9.6	6.8	.218	8.6	6.9	.581
Acute myocardial infarction	2.9	19.8	2.5	< .001	37.4	2.5	< .001
Unstable angina	2.5	33.1	1.7	< .001	62.6	1.7	< .001
Surgical revascularization	1.1	15.1	0.7	< .001	28.5	0.7	< .001
Percutaneous revascularization	1.9	15.9	1.5	< .001	30.0	1.5	< .001
Pacemaker implantation	0.7	2.8	0.7	< .001	3.5	0.7	< .001
ICD implantation	0.7	2.8	0.7	< .001	3.5	0.7	< .001
Ischemic heart disease	4.9	45.8	3.8	< .001	86.4	3.8	< .001
Previous diagnosis of HF	3.0	20.9	2.5	< .001	23.2	2.7	< .001

95%CI, 95% confidence interval; BMI, body mass index; DBP, diastolic blood pressure; HF, heart failure; ICD, implantable cardioverter-defibrillator; SBP, systolic blood pressure.

approximated using Taylor series linearization and the 95%CI was then obtained using the expression:

$$\hat{P} \pm 1.96 \sqrt{\widehat{\text{Var}}(\hat{P})}$$

To identify cardiovascular risk factors and angina-related history, age- and sex-adjusted odds ratios (ORs) were estimated using logistic regression modeling. Subsequently, a multivariate model was constructed to include those factors with $P < .1$ in the univariate analysis.

RESULTS

The mean age of the 8378 participants in the analysis of angina prevalence in the OFRECE study was 59.2 (95%CI, 58.6–59.7) years; 52.6% were women. The general characteristics of the studied population are shown in Table 1, as well as comparisons between patients with definite (Rose questionnaire) or confirmed angina and the rest of the population. The overall population showed high prevalences of risk factors and certain antecedents. Notably, 45.3% of the population was hypertensive, 4.9% had a history of ischemic heart disease, and 3.0% had a diagnosis of heart failure. There were high frequencies of obesity (34%) and overweight (42%).

In the studied population, 210 participants met the Rose questionnaire criteria for definite angina, giving an adjusted prevalence of 2.6% (95%CI, 2.1%–3.1%). Most were in functional class II/IV (64.3%) or I/IV (27.6%) of the New York Heart Association, and only 1.4% were in grade IV/IV. A consideration of confirmed angina could be made in 117 participants (19 after complete evaluation by a cardiologist and the rest due to definite angina and confirmed history of unstable angina, myocardial infarction, or coronary revascularization). The adjusted prevalence of confirmed angina was 1.4% (95%CI, 1.1%–1.8%) (Table 2 and Figure 2). Prevalence increased with age, with very low prevalence of definite angina (Rose) in participants between the ages of 40 and 50 years (< 1%) but progressively increasing to reach 7.1% in those between 70 and 80 years. The prevalences of definite (Rose) and confirmed angina by age and sex groups are presented in Table 2 and Figure 2. According to the Rose questionnaire, 125 (1.5%) and 779 (9.3%) participants met the criteria for possible and atypical angina, respectively.

With the exception of active smoking, there was a higher frequency of coronary risk factors such as obesity, diabetes

mellitus, hypercholesterolemia, and hypertension in patients with angina than in those without angina; patients with angina also showed more comorbidity related to arteriosclerosis (stroke, peripheral artery disease) or possibly caused by it (heart failure) (Tables 3 and 4; Tables 1 and 2 of the supplementary material). The prevalence of definite angina (Rose) tended to be higher in women, but the prevalence of confirmed angina was similar between the sexes (Table 1). In the multivariate analysis (Table 3), definite angina (Rose) was independently associated with age (OR = 1.03), female sex (OR = 1.84), obesity (OR = 1.50), dyslipidemia (OR = 2.52), and history of myocardial infarction (OR = 2.06), unstable angina (OR = 8.71), surgical revascularization (OR = 3.23), or a diagnosis of heart failure (OR = 2.50). The predictors of confirmed angina were age (OR = 1.02), central obesity (OR = 1.69), hypercholesterolemia (OR = 5.36), hypertension (OR = 2.26), peripheral artery disease (OR = 2.12), and history of heart failure (OR = 4.25), but not sex (Table 4).

Of the total population, 4.9% (413 of the 8378 study participants) had a history of ischemic heart disease (documented ACS or revascularization) (Table 1). Application of these data and the specific prevalences of angina by age and sex groups seen in the OFRECE study to the Spanish population (2011 census: 46 815 916 in-habitants, with 51.1% older than 40 years [23 922 933 inhabitants]), taking into account the study design, yields 1 151 350 (95%CI, 995 962–1 306 737) patients with this history of ischemic heart disease in Spain; only 274 480 (95%CI, 197 783–359 177) of these would show symptoms of angina (23.7%; 95%CI, 19.5%–28.0%).

DISCUSSION

The prevalence of stable angina is difficult to establish because its diagnosis is eminently clinical⁴ and complex, expensive population studies are required for a reliable estimation. Most studies have used the Rose questionnaire,¹¹ which, despite its limitations, is recommended by the World Health Organization for epidemiological studies¹² and has been validated for use in Spain.⁸ This questionnaire is useful because it shows a good correlation with cardiovascular morbidity and mortality^{11,12} and has been validated and used in many countries, allowing comparisons with other historical Spanish series and data from other countries.^{16,17} As in most studies, angina was only considered diagnosed when

Table 2

Prevalence of Stable Angina (Definite Angina According to Rose Questionnaire and Confirmed Angina) by Sex and Age Groups

	Men			Women			Total		
	No.	%	95%CI	No.	%	95%CI	No.	%	95%CI
<i>Definite angina (Rose)</i>									
40–49 y	939	0.5	0.0–1.0	1192	0.9	0.3–1.5	2131	0.7	0.3–1.1
50–59 y	912	2.2	1.2–3.2	1090	1.2	0.5–2.0	2002	1.7	1.1–2.4
60–69 y	909	1.5	0.5–2.5	885	2.0	1.0–3.0	1794	1.8	1.1–2.5
70–79 y	706	5.2	2.3–8.1	879	8.6	4.9–12.3	1585	7.1	4.9–9.3
≥ 80 y	373	6.1	2.1–10.2	493	5.3	2.9–7.7	866	5.6	3.5–7.7
Total	3839	2.2	1.6–2.9	4539	2.9	2.2–3.7	8378	2.6	2.1–3.1
<i>Confirmed angina</i>									
40–49 y	939	0.3	0.0–0.8	1192	0.2	0.0–0.5	2131	0.3	0.0–0.6
50–59 y	912	1.5	0.7–2.3	1090	0.6	0.1–1.0	2002	1.0	0.6–1.5
60–69 y	909	0.8	0.1–1.6	885	0.7	0.2–1.2	1794	0.8	0.3–1.2
70–79 y	706	4.5	1.6–7.3	879	4.2	1.9–6.5	1585	4.3	2.6–6.1
≥ 80 y	373	2.9	0.3–5.6	493	2.1	0.5–3.8	866	2.4	1.0–3.8
Total	3839	1.5	1.0–2.1	4539	1.3	0.8–1.7	8378	1.4	1.0–1.8

95%CI, 95% confidence interval.




Figure 2. A, prevalence of definite angina according to the Rose questionnaire (stable angina I) and confirmed angina (stable angina II) by sex and age groups. B, prevalence of history of ischemic heart disease by age groups. IHD, ischemic heart disease.

patients met the definite angina criteria of the Rose questionnaire. The OFRECE study also used a second, more rigorous, definition of angina (confirmed angina), requiring diagnostic confirmation by a cardiologist or documented history of an ACS or coronary revascularization intervention. Few studies have used such stringent criteria, and those studies have also been quite variable, hindering comparisons.

Until the OFRECE study, no population-based re-evaluation of the prevalence of stable angina in Spain had been undertaken since the publication of the PANES study⁸ in 1999. The OFRECE study showed a low prevalence of stable angina in Spain in those aged 40 years or older under either of the definitions used (definite angina, Rose questionnaire: 2.6%; confirmed angina: 1.4%); however, the prevalence increased with age and, as would be

Table 3

Age- and Sex-adjusted Odds Ratios of Having Definite Angina (Rose Questionnaire) for Each Cardiovascular Risk Factor and Antecedent and the Final Multivariate Model

	OR (95%CI)	P
<i>CVRF</i>		
Obesity	1.75 (1.24-2.47)	.001
Overweight	0.74 (0.52-1.06)	.1
Central obesity	1.82 (1.22-2.72)	.004
Hypercholesterolemia	4.05 (2.85-5.75)	<.001
Diabetes mellitus	2.21 (1.39-3.50)	.001
Current smoker	0.58 (0.33-1.00)	.05
Hypertension	1.77 (1.06-2.94)	.028
<i>History</i>		
Stroke	1.60 (0.90-2.86)	.108
Peripheral artery disease	2.85 (1.53-5.32)	.001
Chronic pulmonary disease	1.87 (1.10-3.16)	.02
Thyroid disease	1.39 (0.75-2.58)	.292
Acute myocardial infarction	8.18 (5.09-13.15)	<.001
Unstable angina	22.40 (13.53-37.07)	<.001
Surgical revascularization	19.06 (9.37-38.78)	<.001
Percutaneous revascularization	10.33 (5.46-19.53)	<.001
Pacemaker implantation	2.26 (0.92-5.58)	.076
ICD implantation	2.26 (0.92-5.58)	.076
Ischemic heart disease	19.36 (12.66-29.60)	<.001
Previous diagnosis of HF	5.26 (3.09-8.96)	<.001
<i>Multivariate model</i>		
Age	1.03 (1.01-1.04)	<.001
Sex	1.84 (1.17-2.87)	.008
Obesity	1.50 (1.05-2.15)	.027
Hypercholesterolemia	2.52 (1.66-3.83)	<.001
Acute myocardial infarction	2.06 (1.04-4.07)	.039
Unstable angina	8.71 (4.75-15.96)	<.001
Surgical revascularization	3.23 (1.20-8.69)	.021
Previous diagnosis of HF	2.50 (1.27-4.92)	.008

95%CI, 95% confidence interval; CVRF, cardiovascular risk factor; HF, heart failure; ICD, implantable cardioverter-defibrillator; OR, odds ratio.

expected, the frequency of CVRFs or diseases related to arteriosclerosis was significantly higher in patients with angina. Regardless of the definition used, the prevalence of angina seen in the OFRECE study was much lower than that detected in the other large study of the prevalence of angina carried out more than 15 years ago in Spain (the PANES study). Use of the definite angina (Rose) definition, applied in both studies, reduces the prevalence from 7.6% to 2.6%. This striking decrease probably has a multifactorial explanation that combines methodological and epidemiological aspects. On one hand, the design of the PANES study could allow biases that overestimate prevalence. On the other hand, therapeutic advances and more aggressive management strategies of ACS and stable angina mean that fewer and fewer patients end up with residual angina.^{6,7,17} Undoubtedly, the primary and secondary prevention efforts made by society and health care systems against cardiovascular diseases have also helped to reduce the prevalence of angina. Together, both aspects have probably reduced age-adjusted cardiovascular morbidity and mortality in developed countries.¹⁷⁻²¹ In the present study, only 24% of revascularized patients or those who have had an ACS event were symptomatic. This decreased prevalence in Spain is also seen when we compare our prevalence results with those of the REGICOR study,⁹ published in 1998 (2.6% vs 3.5%). The decreased prevalence of stable angina is in accordance with the trends seen in

Table 4

Age- and Sex-adjusted Odds Ratios of Having Confirmed Angina for Each Cardiovascular Risk Factor and Antecedent and the Final Multivariate Model

	OR (95%CI)	P
<i>CVRF</i>		
Obesity	1.59 (0.92-2.76)	.097
Overweight	0.76 (0.44-1.33)	.337
Central obesity	2.31 (1.40-3.80)	.001
Hypercholesterolemia	6.90 (4.05-11.78)	<.001
Diabetes mellitus	2.00 (1.12-3.57)	.019
Current smoker	0.75 (0.38-1.46)	.398
Hypertension	3.81 (2.14-6.81)	<.001
<i>Antecedent</i>		
Stroke	2.43 (1.21-4.88)	.012
Peripheral artery disease	3.13 (1.44-6.84)	.004
Chronic pulmonary disease	1.98 (1.03-3.82)	.041
Thyroid disease	1.41 (0.57-3.48)	.456
Pacemaker implantation	2.56 (0.86-7.64)	.091
ICD implantation	2.56 (0.86-7.64)	.091
Previous diagnosis of HF	5.60 (2.71-11.59)	<.001
<i>Multivariate model</i>		
Age	1.02 (1.00-1.04)	.036
Sex	0.77 (0.44-1.36)	.369
Central obesity	1.69 (1.03-2.76)	.037
Hypercholesterolemia	5.36 (3.08-9.34)	<.001
Hypertension	2.26 (1.22-4.17)	.009
Peripheral artery disease	2.12 (1.00-4.48)	.049
Previous diagnosis of HF	4.25 (2.09-8.66)	<.001

95%CI, 95% confidence interval; CVRF, cardiovascular risk factor; HF, heart failure; ICD, implantable cardioverter-defibrillator; OR, odds ratio.

the epidemiology of coronary disease in Spain^{22,23} and in the rest of the developed world.¹⁷⁻²¹

This study permitted an estimate of the clinical situation facing patients with chronic coronary disease. For the first time in Spain, the workload can also be estimated: it is clearly high, with more than 1 150 000 patients with history of ischemic heart disease; about 24% of these would have asymptomatic angina. The remainder, more than 850 000, would require health care assistance focused on secondary prevention, which is also a burden for the health care system. Other recent studies^{24,25} show similar data. In the Spanish cohort of the CLARIFY (ProspeCtive observational Longitudinal Registry of patients with stable coronary artery disease) studies,²⁴ comprising 2257 patients with chronic ischemic heart disease, 21.8% had angina. As in the present study, most of these patients were in functional class of the New York Heart Association I/IV or II/IV (33% and 58% of patients, respectively). In the general CLARIFY study,²⁵ 22% of the 33 280 patients with ischemic heart disease had some degree of residual angina.

While we are mindful of the limitations inherent to comparisons between studies conducted using different methodologies and at different times, the prevalence of stable angina in Spain obtained in the OFRECE study seems lower, with either of the 2 definitions used, than that typically described in studies from Europe and the United States. The prevalence of definite angina (Rose) of 2.6% in participants older than 39 years is lower than that estimated for Europe⁴ (2%-4% of the population of all ages) and United States (5%).⁵ This lower prevalence is in line with the characteristically lower rates of coronary disease morbidity and mortality in Mediterranean countries such as Spain.^{20,21}

The characteristics of the patients with stable angina in the OFRECE study are also generally associated with arteriosclerosis (Tables 1, 3 and 4; Tables 1 and 2 of the Supplementary Material): older age and higher rates of CVRFs and of history of cerebrovascular disease, peripheral artery disease, and chronic obstructive pulmonary disease. The profile of patients with angina in this study is similar to that described in other Spanish and international studies.^{4,24–26} One controversial aspect is the prevalence according to sex. Classically, angina has been described as being more frequent in women, whereas the general prevalence of ischemic heart disease and ACS is higher in men. In this study, if the Rose questionnaire definition of angina is used, the prevalence is higher in women (OR = 1.03; 95%CI, 1.01–1.04; $P < .001$) (Tables 1 and 3), whereas no clear differences are seen when a more stringent definition (confirmed angina) is used (OR = 0.77; 95%CI, 0.44–1.36; $P = .369$). The 2 large studies^{16,27} that have analyzed the epidemiological differences in angina between the sexes show similar results to the OFRECE study. Prevalence increased with age, but it was lower in the oldest patients (> 80 years) than in those aged between 70 and 80 years (decreasing from 7.1% to 5.6%) (Table 2 and Figure 2). This drop is probably explained at least in part by the lower survival of patients with ischemic heart disease and the greater limitation of activity due to age-related comorbidity (musculoskeletal system and neurological problems) that avoids reaching the angina threshold.²⁵ The other notable aspect is the negative association between active smoking and angina (definite angina: OR = 0.58; 95%CI, 0.33–1.00) (Table 3). This association is distinct from “smoker’s paradox”, a phenomenon seen in studies from the 1980s and 1990s of a better prognosis for smokers after an ACS and which remains to be reproduced.²⁸ In the present study, the negative association disappears in the multivariate analysis. Thus, smoking does not appear to be an independent factor and was probably associated with angina because most patients with “definite angina” have received guidance on secondary prevention measures.

Limitations

The definitions and criteria of angina used in this study have already been described, as well as their limitations. As in many epidemiological studies, the main study limitations are related to sample selection. In this case, the choice of the health care areas analyzed in each province was not random. We believe that this would have a minimal effect, if any, because the prevalence of angina would be unlikely to vary markedly in adjacent areas. More important is the random selection of physicians and, particularly, of participants linked with each physician, a characteristic of the study design that strengthens the results. The high number of sampling points improved the representativeness of the sample, which can be difficult to evaluate. A limitation inherent to this type of general population study is that the participants can differ from those unable to participate. Although it is impossible to completely discard a potential selection bias, the size of the bias would probably be small because the participation was excellent for this type of study (76% of those whom we tried to contact); only one third of the losses during recruitment were individuals who declined participation.

CONCLUSIONS

The prevalence of stable angina in the Spanish population aged 40 years or older was 2.6% using the Rose questionnaire definition of definite angina and 1.4% when history of ACS or revascularization was also required. The data indicate that the prevalence of stable angina in Spain has decreased in the last decade and is lower than the overall rate observed in Europe and the United States. The prevalence increased with age and an association was seen

between angina and the main CVRFs and history of arteriosclerotic disease.

FUNDING

The OFRECE study was supported by the Research Agency of the Spanish Society of Cardiology (*Agencia de Investigación de la Sociedad Española de Cardiología*). This study has been financed by a grant from the *Observatorio de la Mujer* of the *Agencia de Calidad del Ministerio de Sanidad* and by an unconditional grant from SANOFI (which was not involved in the study design, data analysis, or preparation of the final manuscript).

CONFLICTS OF INTERESTS

None declared.

SUPPLEMENTARY MATERIAL



Supplementary material associated with this article can be found in the online version available at [doi:10.1016/j.rec.2014.09.020](https://doi.org/10.1016/j.rec.2014.09.020).

REFERENCES

- Mensah GA, Brown DW. An overview of cardiovascular disease burden in the United States. *Health Aff (Millwood)*. 2007;26:38–48.
- Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, et al.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Executive summary: heart disease and stroke statistics—2014 update: a report from the American Heart Association. *Circulation*. 2014;129:399–410.
- Flores-Mateo G, Grau M, O’Flaherty M, Ramos R, Elosua R, Violan-Fors C, et al. Análisis de la disminución de la mortalidad por enfermedad coronaria en una población mediterránea: España 1988–2005. *Rev Esp Cardiol*. 2011;64:988–96.
- Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. *Eur Heart J*. 2013;34:2949–3003.
- Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas AP, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS. Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. *J Am Coll Cardiol*. 2012;60:e44–164.
- Rumsfeld JS, Magid DJ, Plomondon ME, Sacks J, Henderson W, Hlatky M, et al.; Department of Veterans Affairs Angina With Extremely Serious Operative Mortality (AWESOME) Investigators. Health-related quality of life after percutaneous coronary intervention versus coronary bypass surgery in high-risk patients with medically refractory ischemia. *J Am Coll Cardiol*. 2003;41:1732–8.
- Rumsfeld JS, McWhinney S, McCarthy Jr M, Shroyer AL, VillaNueva CB, O’Brien M, et al. Participants of the Department of Veterans Affairs Cooperative Study Group on Processes, Structures, and Outcomes of Care in Cardiac Surgery. Health-related quality of life as a predictor of mortality following coronary artery bypass graft surgery. *JAMA*. 1999;281:1298–303.
- Cosín J, Asín E, Marrugat J, Elosua R, Arós F, De los Reyes M, et al.; PANES study group. Prevalence of angina pectoris in Spain. *Eur J Epidemiol*. 1999;15:323–30.
- Masiá R, Pena A, Marrugat J, Sala J, Vila J, Pavesi M, et al.; REGICOR investigators. High prevalence of cardiovascular risk factors in Gerona, Spain, a province with low myocardial infarction incidence. *J Epidemiol Community Health*. 1998;52:707–15.
- Gómez-Doblas JJ, Muñoz J, Alonso Martín JJ, Rodríguez-Roca G, Lobos JM, Awamleh P, et al. Prevalencia de fibrilación auricular en España. Resultados del estudio OFRECE. *Rev Esp Cardiol*. 2014;67:259–69.
- Rose GA, Blackburn H. Cardiovascular survey methods. *Monogr Ser World Health Organ*. 1968;56:1–188.
- Cook DG, Shaper AG, MacFarlane PW. Using the WHO (Rose) angina questionnaire in cardiovascular epidemiology. *Int J Epidemiol*. 1989;18:607–13.
- McNamara RL, Brass LM, Drozda Jr JP, Go AS, Halperin JL, Kerr CR, et al. ACC/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Data Standards on Atrial Fibrillation). *J Am Coll Cardiol*. 2004;44:475–95.
- Silva LC. Diseño razonado de muestras y captación de datos para la investigación sanitaria. Madrid: Díaz de Santos; 2000.

15. Deville JC, Särndal CE. Calibration estimators in survey sampling. *J Am Statist Assoc.* 1992;87:376–82.
16. Hemingway H, Langenberg C, Damant J, Frost C, Pyorala K, Barrett-Connor E. Prevalence of angina in women versus men: a systematic review and meta-analysis of international variations across 31 countries. *Circulation.* 2008;117:1526–36.
17. Garcia-Bermúdez M, Bonet G, Bardají A. Epidemiología de la angina estable y comorbilidad. *Rev Esp Cardiol Supl.* 2012;12(D):3–8.
18. Lampe FC, Morris RW, Whincup PH, Walker M, Ebrahim S, Shaper AG. Is the prevalence of coronary heart disease falling in British men? *Heart.* 2001;86:499–505.
19. Sigurdsson E, Thorgeirsson G, Sigvaldason H, Sigfusson N. Prevalence of coronary heart disease in Icelandic men 1968–1986. The Reykjavik Study *Eur Heart J.* 1993;14:584–91.
20. Levi F, Chatenoud L, Bertuccio P, Lucchini F, Negri E, La Vecchia C. Mortality from cardiovascular and cerebrovascular diseases in Europe and other areas of the world: an update. *Eur J Cardiovasc Prev Rehabil.* 2009;16:333–50.
21. Tunstall-Pedoe H, Kuulasmaa K, Mähönen M, Tolonen H, Ruokokoski E, Amouyel F; WHO MONICA (monitoring trends and determinants in cardiovascular disease) Project. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA Project populations. *Lancet.* 1999;353:1547–57.
22. Banegas JR, Villar F, Graciani A, Rodríguez-Artalejo F. Epidemiología de las enfermedades cardiovasculares en España. *Rev Esp Cardiol Supl.* 2006;6(G):3–12.
23. Ferreira-González I. Epidemiología de la enfermedad coronaria. *Rev Esp Cardiol.* 2014;67:139–44.
24. Zamorano JL, García-Moll X, Ferrari R, Greenlaw N. Características demográficas y clínicas de los pacientes con enfermedad coronaria estable: resultados del registro CLARIFY en España. *Rev Esp Cardiol.* 2014;67:538–44.
25. Ferrari R, Abergel H, Ford I, Fox KM, Greenlaw N, Steg PG, et al.; CLARIFY Investigators. Gender- and age-related differences in clinical presentation and management of outpatients with stable coronary artery disease. *Int J Cardiol.* 2013;167:2938–43.
26. Borrás X, García-Moll X, Gómez-Doblas JJ, Zapata A, Artigas R; investigadores del estudio AVANCE. Estudio de la angina estable en España y su impacto en la calidad de vida del paciente. Registro AVANCE. *Rev Esp Cardiol.* 2012;65:734–41.
27. Hemingway H, McCallum A, Shipley M, Manderbacka K, Martikainen P, Keskimäki I. Incidence and prognostic implications of stable angina pectoris among women and men. *JAMA.* 2006;295:1404–11.
28. Aune E, Roislien J, Mathisen M, Thelle DS, Otterstad JE. The “smoker’s paradox” in patients with acute coronary syndrome: a systematic review. *BMC Med.* 2011;9:97.